Skip To Main Content
Bart Vanhaesebroeck on Muck Rack

Bart Vanhaesebroeck

As seen in: Color Research & Application, Nature, Wiley Online Library, Cell Press, Cancer Discovery, Molecular Cancer Research, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart

Contact Bart, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A renaissance in targeting the PI3K/AKT/mTOR pathway

|
By Sarah E. Conduit, Neil Vasan, Jennifer Brown, Matthew Perry, Bart Vanhaesebroeck
| Nature Verified
Abstract The PI3K/AKT/mTOR pathway represents an excellent drug target, given its proven druggability and roles in cancer, immune regulation and genetic disorders. However, although some agents targeting this pathway have gained approval, drug development has faced challenges due to tolerability issues and resistance mechanisms, amongst other obstacles.
Open in Who Shared Issue with article?

Organismal metabolism regulates the expansion of oncogenic PIK3CA mutant clones in normal esophagus - Nature Genetics

|
By Albert Herms, Bartomeu Colom, Gabriel Piedrafita, Charlotte King, Emilie Abby, David Fernandez-Antoran, Swee Hoe Ong, Roshan K. Sood, Joanna C. Fowler, Christian Frezza, Bart Vanhaesebroeck
| Nature Verified
Abstract Oncogenic PIK3CA mutations generate large clones in aging human esophagus. Here we investigate the behavior of Pik3ca mutant clones in the normal esophageal epithelium of transgenic mice. Expression of a heterozygous Pik3caH1047R mutation drives clonal expansion by tilting cell fate toward proliferation. CRISPR screening and inhibitor treatment of primary esophageal keratinocytes confirmed the PI3K–mTOR pathway increased mutant cell competitive fitness.
Open in Who Shared Issue with article?

30 years of PI3K: an interview with Bart Vanhaesebroeck | Future Oncology

|
By Bart Vanhaesebroeck
| Future Medicine Verified
Could you please introduce yourself & provide a brief summary of your career to date? Many thanks for this interview – my answers below are targeted at a wider nonspecialist audience. I am a basic scientist with a keen interest in applying newly acquired knowledge to understand and treat human disease. Throughout my research career, I have always been involved in fundamental research that could be applied to drug development.
Open in Who Shared Issue with article?
See all 12 articles